Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-26-054381
Filing Date
2026-08-06
Accepted
2026-08-06 16:32:18
Documents
73
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ird-20260630.htm   iXBRL 10-Q 1223507
2 EX-31.1 ird-20260630xex311.htm EX-31.1 10533
3 EX-31.2 ird-20260630xex312.htm EX-31.2 10892
4 EX-32.1 ird-20260630xex321.htm EX-32.1 6664
  Complete submission text file 0001628280-26-054381.txt   7345555

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ird-20260630.xsd EX-101.SCH 70385
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ird-20260630_cal.xml EX-101.CAL 53293
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ird-20260630_def.xml EX-101.DEF 370451
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ird-20260630_lab.xml EX-101.LAB 735694
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ird-20260630_pre.xml EX-101.PRE 525211
77 EXTRACTED XBRL INSTANCE DOCUMENT ird-20260630_htm.xml XML 777488
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 (984) 884-6030
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 261249740
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)